Watanabe M, Kitamura Y, Komatsubara S, Sakata Y
Department of Urology, Niigata Cancer Center Hospital.
Hinyokika Kiyo. 1988 Dec;34(12):2135-41.
Between June, 1986 and December, 1987, the serum gamma-Sm and PAP was measured in 29 men with untreated prostatic cancer, 45 with treated prostatic cancer (32 were well-controlled and 13 poorly controlled), 82 with benign prostatic hypertrophy and 10 with other urological diseases. All of the patients with prostatic cancer had histologically proven disease. Enzyme immunoassay for gamma-Sm and radioimmunoassay for PAP were used. The cut-off value for gamma-Sm was 4 ng/ml and that for PAP was 3 ng/ml. The mean values of gamma-Sm and PAP were statistically high in the untreated group and also in poorly-controlled group. In the untreated group, the rate of positivity for gamma-Sm and for PAP were 69% respectively and 83% of the patients had elevated values for either or both of these markers. In clinical stage A and B, gamma-Sm and PAP values were within the normal limit, however the concentrations of mean gamma-Sm and PAP correlated well with the stage of disease. In the poorly-controlled group, positive gamma-Sm values were detected in 75% and PAP in 67%, whereas almost all of the patients had normal values for these markers in the well-controlled group. In prostatic hypertrophy, elevated gamma-Sm values were detected in 15% and elevated PAP values in 6%. After the onset of treatment, elevated values were normalized in 66.7% of the patients for gamma-Sm and in 68.4% for PAP. In the untreated group, gamma-Sm tended to show a more prompt response. In the ill-controlled group, gamma-Sm and PAP returned to normal in 50% of the patients. gamma-Sm and PAP values were well correlated with the course of the prostatic cancer and the clinical usefulness became more obvious with a combination of these markers.
1986年6月至1987年12月期间，对29例未经治疗的前列腺癌男性患者、45例接受过治疗的前列腺癌患者（其中32例病情得到良好控制，13例控制不佳）、82例良性前列腺增生患者以及10例患有其他泌尿系统疾病的患者进行了血清γ-精浆蛋白（gamma-Sm）和前列腺酸性磷酸酶（PAP）检测。所有前列腺癌患者均经组织学证实患有该病。采用酶免疫分析法检测γ-精浆蛋白，放射免疫分析法检测前列腺酸性磷酸酶。γ-精浆蛋白的临界值为4 ng/ml，前列腺酸性磷酸酶的临界值为3 ng/ml。未经治疗组以及控制不佳组的γ-精浆蛋白和前列腺酸性磷酸酶平均值在统计学上均较高。在未经治疗组中，γ-精浆蛋白和前列腺酸性磷酸酶的阳性率分别为69%，83%的患者这两种标志物中的一种或两种值升高。在临床A期和B期，γ-精浆蛋白和前列腺酸性磷酸酶值在正常范围内，然而γ-精浆蛋白和前列腺酸性磷酸酶的平均浓度与疾病分期密切相关。在控制不佳组中，75%的患者γ-精浆蛋白值呈阳性，67%的患者前列腺酸性磷酸酶值呈阳性，而在控制良好组中，几乎所有患者这些标志物的值均正常。在前列腺增生患者中，15%的患者γ-精浆蛋白值升高，6%的患者前列腺酸性磷酸酶值升高。治疗开始后，66.7%的患者γ-精浆蛋白值恢复正常，68.4%的患者前列腺酸性磷酸酶值恢复正常。在未经治疗组中，γ-精浆蛋白往往显示出更迅速的反应。在控制不佳组中，50%的患者γ-精浆蛋白和前列腺酸性磷酸酶恢复正常。γ-精浆蛋白和前列腺酸性磷酸酶值与前列腺癌病程密切相关，联合使用这两种标志物其临床实用性更为明显。
